Idoxuridine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Ophth Herpes simplex keratitis As 0.1% soln: Instill 1 drop hrly. Taper to 2 hrly or 4 times/day, continue treatment for at least 7 days. Topical Cutaneous herpes simplex and herpes zoster As 5% preparation: Apply 4 times/day for 4 days.
Dosage Details
Ophthalmic
Herpes simplex keratitis
Adult: As 0.1% soln: Instill 1 drop in the affected eye(s) every hr. Taper to every 2 hr or 4 times daily. Continue treatment for at least 7 days.

Topical/Cutaneous
Cutaneous herpes simplex and herpes zoster
Adult: As 5% preparation: Paint onto the lesions 4 times daily for 4 days.
Contraindications
Hypersensitivity.
Special Precautions
Deep ulceration of the stromal layers of the cornea. Avoid prolonged use. Pregnancy and lactation.
Adverse Reactions
Ophthalmic: Irritation; inflammation of the eye or eyelids; pain; photophobia; pruritus; conjunctivitis; oedema. Rarely, lachrymal duct occlusion and hypersensitivity reactions. Corneal damage (prolonged use). Topical: Irritation; stinging; hypersensitivity reactions; corneal punctate defects or skin maceration (when applied excessively).
Drug Interactions
Corticosteroids may accelerate spread of viral infection.
Action
Description: Idoxuridine, a pyrimidine nucleoside structurally related to thymidine, inhibits viral replication by substituting itself for thymidine in viral DNA. It is active against herpes simplex and varicella zoster viruses, and has also been shown to inhibit vaccinia virus, cytomegalovirus and adenovirus.
Pharmacokinetics:
Absorption: Poor penetration into the skin and cornea.
Metabolism: Metabolised rapidly in the body to iodouracil, uracil and iodide.
Excretion: Metabolites are excreted in the urine.
Storage
Ophthalmic:
Store between 36-80°F.
Disclaimer: This information is independently developed by MIMS based on Idoxuridine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in